NCT04108936 Longitudinal Study of CRS/HIPEC for Peritoneal Carcinomatoses
| NCT ID | NCT04108936 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Regensburg |
| Condition | Peritoneal Carcinomatosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2016-10 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2016-10 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Longitudinal Study of the Effect of Cytoreductive Surgery and HIPEC in Patients With Peritoneal Carcinomatoses
Eligibility Criteria
Inclusion Criteria: * suspicious peritoneal carcinomatosis Exclusion Criteria: * \<18 years
Contact & Investigator
Matthias Hornung, MD
STUDY DIRECTOR
Dept. of Surgery, University Hospital Regensburg
Frequently Asked Questions
Who can join the NCT04108936 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Peritoneal Carcinomatosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04108936 currently recruiting?
Yes, NCT04108936 is actively recruiting participants. Contact the research team at Jens.Werner@ukr.de for enrollment information.
Where is the NCT04108936 trial being conducted?
This trial is being conducted at Regensburg, Germany, Regensburg, Germany.
Who is sponsoring the NCT04108936 clinical trial?
NCT04108936 is sponsored by University of Regensburg. The principal investigator is Matthias Hornung, MD at Dept. of Surgery, University Hospital Regensburg. The trial plans to enroll 250 participants.